TRIMTECH Therapeutics brings total seed round to $47M with additional investment of $14M to further develop TRIMTAC and TRIMGLUE targeted protein degradation portfolio
- Johnson & Johnson’s corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc. (“JJDC”), and BGF join existing investors Cambridge Innovation Capital, DDF, M Ventures, Pfizer Ventures, Eli Lilly and Company, MP Healthcare Venture Management (MPH), Cambridge Enterprise Ventures
Cambridge, UK, 23 June 2026: TRIMTECH Therapeutics (TRIMTECH or the Company), a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced it has raised an additional $14 million in seed funding, bringing the total for the round to $47 million (£35 million). The financing was led by Johnson & Johnson’s corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc. (“JJDC”), and BGF, who join existing investors. This new funding will support the Company as it progresses its proprietary platforms and differentiated portfolio.
Founded on decades of pioneering academic research into the protein TRIM21, a novel E3-ligase, TRIMTECH has demonstrated its TRIMTAC® and TRIMGLUE® degraders can selectively degrade toxic protein aggregates and oligomers whilst leaving the functional monomeric forms of these proteins intact to support healthy cellular function. This opens up much needed small molecule approaches for indications that affect very large populations. With over 55 million people affected by Alzheimer’s disease and millions more battling other neurodegenerative disorders, this groundbreaking innovation has the potential to transform the course of treatment for these patients.
Dr Nicki Thompson, CEO, TRIMTECH Therapeutics, said: “We welcome JJDC and BGF as investors in our seed financing round and thank them for their support. This additional funding allows us to forge ahead with developing our portfolio of CNS penetrant degraders based on our unique platforms. TRIMTECH has incredibly strong scientific foundations combined with a world leading team augmented by a globally recognised investor syndicate – I’m excited to work with this exceptional group, to deliver the next phase of growth for the company.”
Following this seed extension round, representatives from JJDC and BGF, will join TRIMTECH Therapeutics Board as non-executive directors.
ENDS
Contact:
Zyme Communications
Katie Odgaard
Katie.odgaard@zymecommunications.com
About TRIMTECH Therapeutics Ltd.
TRIMTECH Therapeutics is creating novel, highly selective, small molecule targeted protein degraders, to combat neurodegenerative and inflammatory diseases. Founded on decades of pioneering academic research into the protein TRIM21, a novel E3-ligase, the Company has demonstrated its ‘TRIMTAC’ degraders can recapitulate degradation seen with other modalities (vectors and antibodies) whilst leaving the functional monomeric form of the target protein intact and able to support healthy cellular function. TRIMTECH’s approach opens up much needed small molecule approaches for indications that affect very large populations, such as Alzheimer’s disease.
TRIMTECH was founded in 2023 by its academic co-founders Leo James, PhD FRS (MRC Laboratory of Molecular Biology) and Will McEwan, PhD (UK Dementia Research Institute, University of Cambridge), with Cambridge Innovation Capital (CIC) and SV Health Investors’ Dementia Discovery Fund (DDF) in conjunction with their joint entrepreneur-in-residence, Dr Damian Crowther.
TRIMTECH is led by a highly experienced team with vast expertise in targeted protein degradation (TPD). In 2025, the Company announced its $31 million (£25 million) seed funding round, led by CIC and DDF, with M Ventures and Pfizer Ventures joining. Additional investors also include Eli Lilly and Company, MP Healthcare Venture Management (MPH), Cambridge Enterprise Ventures, and Start Codon.
For more information, visit: www.trimtechtherapeutics.com. Find TRIMTECH on LinkedIn and Bluesky.
